CL2025002665A1 - Composición farmacéutico y uso para el tratamiento de la atrofia muscular espinal. - Google Patents

Composición farmacéutico y uso para el tratamiento de la atrofia muscular espinal.

Info

Publication number
CL2025002665A1
CL2025002665A1 CL2025002665A CL2025002665A CL2025002665A1 CL 2025002665 A1 CL2025002665 A1 CL 2025002665A1 CL 2025002665 A CL2025002665 A CL 2025002665A CL 2025002665 A CL2025002665 A CL 2025002665A CL 2025002665 A1 CL2025002665 A1 CL 2025002665A1
Authority
CL
Chile
Prior art keywords
pharmaceutical composition
muscular atrophy
spinal muscular
treatment
oxazol
Prior art date
Application number
CL2025002665A
Other languages
English (en)
Inventor
Holm Pedersen Thomas
Skjærlund Grønnebæk Thomas
Brandhøj Skov Martin
Rose Chin Eva
Mary Bold Jane
Armando Bastias Jorge
Original Assignee
Nmd Pharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nmd Pharma As filed Critical Nmd Pharma As
Publication of CL2025002665A1 publication Critical patent/CL2025002665A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

En la presente se divulgan métodos de tratamiento de la atrofia muscular espinal (SMA) que implican la administración del ácido (2S)-2-[4-bromo-2-(1,2-oxazol-3-il)fenoxi]propanoico (NMD670), un compuesto inhibidor de canales cloruro del músculo esquelético (CIC-1), o una composición farmacéutica de este, a un paciente que padece síntomas de SMA. También se divulgan composiciones farmacéuticas y kits de partes que incluyen ácido (2S)-2-[4-bromo-2-(1,2-oxazol-5 3-il)fenoxi]propanoico.
CL2025002665A 2023-03-02 2025-09-01 Composición farmacéutico y uso para el tratamiento de la atrofia muscular espinal. CL2025002665A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202363488055P 2023-03-02 2023-03-02
EP23162356 2023-03-16
EP23208554 2023-11-08

Publications (1)

Publication Number Publication Date
CL2025002665A1 true CL2025002665A1 (es) 2025-12-19

Family

ID=90059423

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2025002665A CL2025002665A1 (es) 2023-03-02 2025-09-01 Composición farmacéutico y uso para el tratamiento de la atrofia muscular espinal.

Country Status (10)

Country Link
EP (1) EP4673143A1 (es)
JP (1) JP2026508357A (es)
KR (1) KR20250160957A (es)
CN (1) CN121175046A (es)
AU (1) AU2024229683A1 (es)
CL (1) CL2025002665A1 (es)
IL (1) IL321850A (es)
MX (1) MX2025010235A (es)
TW (1) TW202502329A (es)
WO (1) WO2024180201A1 (es)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10385028B2 (en) * 2017-12-14 2019-08-20 Nmd Pharma A/S Compounds for the treatment of neuromuscular disorders
US12440477B2 (en) * 2017-12-14 2025-10-14 Nmd Pharma A/S Compounds for the treatment of neuromuscular disorders
US20200237931A1 (en) * 2019-01-25 2020-07-30 Oxford University Innovation Limited Molecules targeting survival motor neuron 2
BR112021025588A2 (pt) 2019-06-19 2022-02-01 Nmd Pharma As Processo para a preparação dos inibidores de canal de cloreto clc-1

Also Published As

Publication number Publication date
TW202502329A (zh) 2025-01-16
KR20250160957A (ko) 2025-11-14
CN121175046A (zh) 2025-12-19
JP2026508357A (ja) 2026-03-10
EP4673143A1 (en) 2026-01-07
WO2024180201A1 (en) 2024-09-06
MX2025010235A (es) 2025-10-01
IL321850A (en) 2025-08-01
AU2024229683A1 (en) 2025-07-24

Similar Documents

Publication Publication Date Title
BR0312095A (pt) Composto, composição farmacêutica, e, uso de um composto
BRPI0512213A (pt) método para tratamento, prevenção ou melhora de uma doença ou distúrbio; composição farmacêutica; processo para a preparação de um composto; e uso de um composto
BR0306872A (pt) Composições e métodos de tratamento envolvendo agonistas do receptor-gama ativado pelo proliferador de peroxissoma e inibidores seletivos da ciclooxigenase-2
BRPI0408256A (pt) composto, métodos de tratamento de um humano ou animal, pela limitação da replicação de células, que sofre de cáncer, que sofre de uma doença neoplástica, e que se sofre de doenças proliferativas, uso de um composto, e, processo para a preparação de um composto ou de um seu sal farmaceuticamente aceitável ou de um éster hidrolisável in vivo do mesmo
BRPI0408236A (pt) método para radiofluoração, composto, composição radiofarmacêutica, uso de um composto, e, métodos para gerar uma imagem de um corpo humano ou animal e para monitorar o efeito de tratamento de um corpo humano ou animal com um medicamento para combater uma condição associada com cáncer
BR0116370A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento de uma doença ou condição mediada por hppar em um paciente.
BR112018005454A2 (pt) administração de potencializadores de cftr deuterados
EA201170969A1 (ru) Новые макроциклические ингибиторы репликации вируса гепатита с
BR0315720A (pt) Composto, método para a profilaxia ou tratamento de uma condição clìnica em um mamìmefero, formulação farmacêutica, combinação, uso de um composto, processo para a preparação de um composto, e, intermediário
BRPI0819451A2 (pt) Composição farmacêutica, método para tratar dor, kit farmacêutico, e, uso de uma composição
RU2011139107A (ru) Специфические соединения диарилгидантоина и диарилтиогидантоина
CR20240043A (es) Compuestos de heteroarilo para tratar la enfermedad de huntington
AR060089A1 (es) Tratamiento del dolor
BR112018072339A2 (pt) tratamento de distúrbios de perda de cabelo com inibidores de jak deuterados
BR112016028876A2 (pt) composto, composição farmacêutica, método para tratar uma doença ou condição em um ser humano, kit, e, uso de um composto, um sal, isômero ou uma mistura farmaceuticamente aceitável dos mesmos.
BRPI0410316A (pt) composto, composição farmacêutica, uso dos compostos, e, método de tratamento de distúrbios mediados por vr1 e para o tratamento de distúrbios de dores
BR0309343A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento ou profilaxia de doenças ou condições humanas
CL2022000458A1 (es) Ciertos compuestos de pladienolida y métodos de uso. (divisional de solicitud 202002604)
RU2003133924A (ru) Дейтерированные 3-пиперидиноэтилфенилкетоны, а также лекарственные средства, содержащие эти соединения
BR0316458A (pt) Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, método para intensificar a cognição em um paciente saudável, e, uso de um composto
CL2021003312A1 (es) Composición que comprende pridopidina y un análogo de la misma para el tratamiento de la enfermedad de huntington y síntomas de la misma.
WO2023043870A8 (en) Chewing gum formulation of lsd and methods of use thereof
MX2024014435A (es) Compuestos heterociclicos y heteroarilo para el tratamiento de la enfermedad de huntington
MX2019001412A (es) Compuestos de 9-aminometil minociclina y usos de los mismos.
CL2025002665A1 (es) Composición farmacéutico y uso para el tratamiento de la atrofia muscular espinal.